Latus Therapeutics Limited, founded in 2019, is a leading research and experimental development biotech company with a vision to find a cure for cancer. We are specifically looking at the B-cell Lymphomas and autoimmune disorders in order to get a better understanding of the underlying signalling mechanism of the cell and its potential in helping people to combat cancer.
Today, in response to the public health crisis, Latus Therapeutics has refocused its efforts to originate not for profit initiative to find a treatment for the patients tested positive with the COVID-19. At a time when thousands of people around the world are dying every day from the disease and economies are paralysed, this crucial research will utilise existing medicines that have already been shown to prevent the virus from infecting human cells in vitro. More information about the trials can be found on our website. Latus' team is contributing their time for free.
News
New drugs could halt spread of killer coronavirus | Express, April 26, 2020
UK SCIENTISTS are working on a groundbreaking new treatment for Covid-19 which "stops the virus in its tracks". Experts say the drug - which is already approved for human use - could be used to prevent people catching coronavirus as well as to treat those already infected.
Team
Founder - SPIKE trials
Managing Director of the
Latus Therapeutics
Dr. S. Anthony
Clinical Advisor - SPIKE trials
Honorary Senior Clinical Lecturer in Radiology,
Oxford University Hospital
Prof. D. Anthony
Scientific Advisor - SPIKE trials
Department of Pharmacology,
University of Oxford
Scientific Advisor - SPIKE trials
Chairman of Oxford Drug Design
Founder of Oxford University Innovation
Ex-Head of Chemistry Department,
University of Oxford
Dr C. Ferrett
Trial Coordinator - SPIKE trials
Consultant Radiologist
Oxford University Hospital
Dr. E. Ladds
Clinical Advisor - SPIKE trials
Academic Clinical Fellow, Primary Care,
Oxford University
